Biopharmaceuticals Market Intelligence

The significance of biopharmaceuticals in today’s world is immense! These products have transformed the treatment landscape for several previously untreatable ailments such as autoimmune disorders, rare genetic diseases, cancer and infectious outbreaks. They now account a major portion of share in the holistic pharmaceutical sales, and the number is continuously rising. World’s top selling therapies such as adalimumab, pembrolizumab, and new mRNA vaccines are all biopharmaceuticals.

But what makes this space especially challenging and exciting right now is its rapid diversification. It is no longer just about blockbuster biologics but the next wave of biopharmaceuticals is driven by:

mRNA 2.0 platforms entering oncology
Biosimilar wars heating up in the U.S. post-Humira loss of exclusivity
Off the shelf CAR-T therapies approaching commercial reality
Cell and gene therapy QC, which is quietly becoming the next billion-dollar niche
AI in biopharmaceutical design, slashing discovery timeframe from years to months

At the same time, developers are grappling with scale up inefficiencies, price sensitivity, and growing complex regulatory pathways. That’s where we come in!

Our offered insights across the biopharmaceutical cluster brings clarity to this complexity, curating forward looking comprehensions across some high impacting categories. From early R&D to commercial launch, we help you decide what’s next, detect whitespace, and act with data-backed solutions in a landscape that evolves by the minute.

Topics Covered

Vaccines

The global market size for vaccines market is USD 67.52 Billion in 2024.
Post-COVID stabilization hasn’t slowed innovation as next-gen vaccines now focus on universal flu, RSV, and cancer.
mRNA 2.0, adjuvant science, and thermostable formats are hot focus areas.
Our study focuses on the market view of therapeutic vaccines such as monovalent and multivalent, technology platforms (mRNA, viral vectors), route of administration, disease indication, age group, and several trends impacting the industry such as global immunization trends, pipeline trends etc.

Monoclonal Antibodies

The backbone of targeted therapy, mAbs dominate oncology and immunology treatment pipelines.
Monoclonal antibodies are reshaping the innovation curves with a market size of USD 254.22 billion in 2024.
Our study specifically targets the market outlook on type such as Human mAbs, Humanized mAbs, Chimeric and Murine mAbs, disease-specific applications analysis, distribution channel analysis, regulatory pathways, trends and others.

Cell and Gene Therapy Manufacturing QC

Quality control is a mission critical function in the CGT scale up which now hold around USD 2.24 Billion market size in 2024.
Complex assays, vector validation and potency testing are creating niche opportunities in a traditionally underserved segment.
Our study focuses on insights regarding analytical methods for therapy type such as cell and gene therapy, by scale of manufacturing, by mode of testing, by workflow, process and end user analysis.

Biosimilars

A cost competitive alternative to branded biologics, biosimilars are gaining strong regulatory momentum post the loss of exclusivity of biologics in the U.S.
Our study shall entail into the world of biosimilars with striking insights on approval landscapes, competitive pricing, analysis by drug class such as Filgrastim biosimilars, including Zarxio and Nivestym. Pipeline analysis, recent trends etc.

Recombinant Proteins

These biologics remain essential across chronic diseases and rare conditions.
Platform flexibility and biosimilar penetration are key trends here.
Our report focuses on the trends in therapeutic and research-grade protein production, analysis on type of products such as cytokines & growth factors. Analysis on host cells, expression systems, and purification technologies.

Regenerative Medicine

Encompassing stem cell therapies and tissue engineering, regenerative medicine holds promise in orthopedics, neurology, and cardiovascular repair.
Most players still sit in pre-commercial phases or restricted clinical use.
Our report specifically focuses on cell-based immunotherapy products, cord blood / progenitor cell therapies, tissue engineering, and emerging applications in orthopedics, oncology, infectious disease, etc.

RNA Therapy

Beyond vaccines, RNA interference (RNAi) and antisense oligonucleotides are making waves in rare genetic disorders.
Improved delivery systems and lower immunogenicity are unlocking new indications.
Our report focuses on the analysis of mRNA, siRNA, and antisense oligonucleotide therapies, delivery platforms, and clinical development pipeline.

Antibody Drug Conjugates (ADC)

ADCs combine antibody specificity with cytotoxic payloads revolutionizing targeted oncology.
Our study focuses on the overview and analysis of ADCs such as Kadcyla, Enhertu, Adcetris, etc. technology analysis, pipeline insights on ADCs, disease application analysis, regional analysis, recent trends and impact analysis.

Blood Products

Includes plasma-derived therapies like immunoglobulins and clotting factors.
Used in immune deficiency, trauma, and hemophilia care supply constraints and donor dependency remain key concerns.
Overview of plasma-derived products, red cells, platelets, and recombinant alternatives, with insights on supply chains and donor regulations.

Cell and Gene Therapy (CGT)

With thousands of candidates in pipeline, CGTs are rewriting how we approach rare, genetic, and hematologic diseases.
The move toward off-the-shelf allogeneic models is critical for access and affordability.
Comprehensive coverage of cell and gene therapies. Analysis on disease indications, end user etc. Further pipeline analysis, trends and regulatory landscapes.

What you unlock in the Biopharmaceutical Cluster

Whether you are scaling CGT production, or entering the ADC space, or benchmarking pricing; our offerings empower your strategy with the data that matters!

Market Intelligence Hub

Detailed market landscaping across several biopharma categories including market sizing, regulatory climate, competitive intensity, country level assessment etc.

Forecast Dashboard

8 Years of Market revenue dashboards with 4 years of forecast, and 4 years of historical data!
Global revenues categorized by region and country level analysis.

Country Level Analysis

Tailored analysis of each country’s market landscape, highlighting trends, growth levers, roadblocks, and fresh developments.

Emerging Trend Radar

Stay ahead of the curve with detailed insights on:

Evolutionary Development & Serialized Approvals of Monoclonal Antibodies in U.S. and Europe
Global Monoclonal Antibodies Pipeline
Vaccines Pipeline Analysis
Global Vaccination Coverage
Vaccine Stock out & Supply Chain Analysis
Vaccines Procurement & Deliveries
Vaccine Approvals by Manufacturers
Gene Therapy Pipeline Analysis
Innovative Technologies Driving the Future of Cell & Gene Therapy

And many more additions coming your way, driven by emerging trends designed to accelerate your business from every angle!

Company Briefing

Detailed analysis of leading and emerging players in the space!

Segmental Analysis

Combines in-depth data and strategic narratives across countries and regions, tailored to every segment we cover.

Sources & Citations

Every data point, forecast or qualitative insights is backed by credible primary and secondary sources and shall be provided for validation.

Company Market Share Analysis

Quantitative assessment of market shares by revenues at the global OR regional level

KOL + Payer Insights

What do experts really think?
Transcripts of real world interviews with clinicians, manufacturers, regulators etc.

In the News” or Trending Insights Strip

Recent news in the biopharma industry including FDA approvals, big M&A deals, policy changes, helps show your portal stays updated and plugged into real time events.

Decoding the Market Pulse: Key Market Indicators We Analyzed to Map the Momentum

Indicators	What It Tells Us
Advanced Therapies and Biologics Pipeline Density	We track the number of active phase trials and regulatory filings for RNA, CGT, monoclonal, ADCs, which indicates investments zones and hotspots!
Regulatory Acceleration (e.g.: RMAT, PRIME, Fast Track)	We evaluate the total number of therapies in this cluster receiving expedited pathways, indicating early signals of future industry disruptors, especially in oncology and rare diseases.
CDMO demand and Manufacturing Scalability	We map facility expansions, vector manufacturing demands, and single use technology adoption, which are the key momentum for the cell and gene therapy QC and recombinant proteins sectors.
Biosimilar Launch Post- Loss Of Exclusivity	We analyze the success rates and the rate of biosimilar launches post exclusivity (e.g.: Humira in the U.S.), indicating payer interest, price erosion risk, competitive saturation etc.
KOL & Payer Sentiment Shift	We extrapolate data from HTA trends and clinician interviews which reveals shifting adoption behavior around the off the shelf CAR-Ts, ADCs, and RNA therapies.
Real World Evidence (RWE) Uptake	We analyze how biopharmaceutical companies are integrating RWE into market access and regulatory strategies, especially relevant for CGTs, vaccines and rare disease products.
Biopharma M&A and Licensing Trends	We analyze the changes in reference pricing, pricing policy, and outcome based contracts, specifically relevant across the biosimilar, vaccines and ADCs.
APAC and Emerging Market Biologics Uptake	We track adoption rates of affordable biologics and biosimilar in India, LATAM, MEA, leading indicators for volume based growth plays in these regions.
Number of Clinical Trials	We analyze the expansion of the CGT, advanced therapies pipeline. This helps access regional innovation hubs, global contributions, and late stage trials in progress.
Import-Export Trade Flow Index	We monitor the shifts in global vaccine production and trade routes. Helps identify geopolitical supply chain risks.

Before First IQ

You're struggling to find reliable market research, wasting time and resources on incomplete data.
Your business decisions are based on assumptions, not facts, putting your company at risk.
You're falling behind competitors who have access to better insights.

Bridge:

First IQ is the connection between uncertainty and confidence, between assumptions and facts.
Our platform bridges the gap between data and insights, providing a clear understanding of your market.
With First IQ, you can transition from uncertainty to clarity, unlocking your business's true potential.

After First IQ

With First IQ, you have instant access to comprehensive market research, empowering informed decisions.
You're equipped with actionable insights, identifying new opportunities and staying ahead of industry trends.
Your business thrives, outpacing competitors and achieving its full potential.

Biopharmaceuticals

Biopharmaceuticals Market Intelligence

Topics Covered